People: Venaxis Inc (APPY.PH)

APPY.PH on Philadelphia Stock Exchange

1.88USD
2:51pm EDT
Price Change (% chg)

$-0.05 (-2.85%)
Prev Close
$1.93
Open
$1.88
Day's High
$1.88
Day's Low
$1.88
Volume
200
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Gail Schoettler

65 2010 Non-Executive Independent Chairman of the Board

Stephen Lundy

51 2010 President, Chief Executive Officer, Director

Jeffrey McGonegal

62 2010 Chief Financial Officer, Corporate Secretary

Donald Hurd

61 2012 Senior Vice President, Chief Commercial Officer

Susan Evans

66 2013 Independent Director

Daryl Faulkner

65 2010 Independent Director

John Landon

72 2008 Independent Director

David Welch

66 2004 Independent Director

Stephen Williams

2013 Independent Director

Joshua Drumm

IR Contact Officer

Biographies

Name Description

Gail Schoettler

Ambassador Dr. Gail S. Schoettler is Non-Executive Independent Chairman of the Board of Venaxis, Inc. In October 2010, Ms. Schoettler became Non-Executive Chair of the Board. She also serves on the board and is a member of the audit committee of Delta Dental of Colorado, a non-profit dental insurance company. She serves on the boards of The Colorado Trust and the Delta Dental Foundation. Former corporate board positions include: Masergy Communications, Inc., CancerVax, Inc., PepperBall Technologies, Inc., AirGate PCS, Women’s Bank, Equitable Bancshares of Colorado, the Colorado Public Employees Retirement Association and Fischer Imaging. She has served as a U.S. Ambassador, appointed by President Clinton, and as Colorado’s Lt. Governor and State Treasurer. In 1998, she narrowly lost her bid for Governor of Colorado. She started two banks and helps run her cattle ranch (where she grew up), vineyards, and real estate enterprises. She earned a B.A. in economics from Stanford and M.A. and Ph.D. degrees in African history from the University of California at Santa Barbara. Among her numerous awards is the French Legion of Honor (France’s highest civilian award) from President Jacques Chirac of France.

Stephen Lundy

Mr. Stephen T. Lundy is President, Chief Executive Officer, Director of Venaxis, Inc. since March 24, 2010. Effective on the same date, he was appointed to Board of Directors. Mr. Lundy has more than 20 years of experience in drug and diagnostic product development and commercialization. He most recently was Chief Executive Officer of MicroPhage from 2008 to 2010. Mr. Lundy was Senior Vice President of sales and marketing for Vermillion from 2007 to 2008. Mr. Lundy joined Vermillion from GeneOhm (2003-2007), a division of Becton, Dickinson and Company Diagnostics, where he served as Vice President of Sales and Marketing. At GeneOhm, Mr. Lundy led the commercial launch of several novel molecular diagnostic assays including the first molecular test for Methicillin resistant Staphylococcus aureus. From 2002 to 2003, Mr. Lundy served as Vice President of Marketing for Esoterix, Inc., which was acquired by Laboratory Corporation of America, and he led the commercial integration and re-branding of the numerous reference labs acquired by Esoterix. Prior to Esoterix, he served as Marketing Director for Molecular Diagnostics and Critical Care Testing at Bayer Diagnostics Corporation. Mr. Lundy graduated from the United States Air Force Academy with a B.S. degree and was an officer with the United States Air Force from 1983 to 1988.

Jeffrey McGonegal

Mr. Jeffrey G. McGonegal is Chief Financial Officer, Corporate Secretary of Venaxis, Inc. He became Chief Financial Officer of the Company in June 2003, was appointed Corporate Secretary in January 2010 and served as interim President in December 2004 and January 2005. Mr. McGonegal served from 2003 to January 1, 2011 as Chief Financial Officer of PepperBall Technologies, Inc. Mr. McGonegal also serves on a limited part-time basis as Senior Vice President — Finance of Cambridge Holdings, Ltd., a small publicly held company with limited business activities. Mr. McGonegal served as Chief Financial Officer of Bactolac Pharmaceutical, Inc. and had been associated with its predecessors through October 2006, a company (publicly held until September 2006) engaged in manufacturing and marketing of vitamins and nutritional supplements. From 1974 to 1997, Mr. McGonegal was an accountant with BDO Seidman LLP. While at BDO Seidman LLP, Mr. McGonegal served as Managing Partner of the Denver, Colorado office. Until his resignation in March 2012, Mr. McGonegal was elected in 2005 to serve on the board of Imagenetix, Inc., a publicly held company in the nutritional supplements industry. He received a B.A. degree in accounting from Florida State University.

Donald Hurd

Mr. Donald R. Hurd is the Senior Vice President and Chief Commercial Officer of Venaxis, Inc. He is a seasoned executive with over 30 years of experience in the medical diagnostic and device industry, having worked in diagnostic companies as well as start-ups. Mr. Hurd joined Venaxis from BioBehavorial Diagnostics where he most recently served as Vice President-Sales from July 2010 to March 2012. Prior industry positions include Vice President-Marketing/Sales at MicroPhage, Vice President North American Customer Operations, Siemens Healthcare Diagnostics, U.S. Director of Sales, Bayer Healthcare Diagnostics. Mr. Hurd received a B.S. in business administration and is a military veteran with the United States Navy.

Susan Evans

Dr. Susan A. Evans, Ph.D., FACB, is Independent Director of Venaxis, Inc., since January 1, 2013. Dr. Evans is the Vice President, Scientific Affairs, of the Beckman Coulter division of Danaher, Inc., a position she has held since 2006. Previously she served as Vice President, Corporate Strategic Planning for Beckman Coulter from January 2010 to July 2011, and as Vice President and General Manager of Agencourt Bioscience, a Beckman Coulter company from December 2006 to January 2010. She has more than 30 years of experience in the diagnostic industry, holding leadership positions in research and development and now general management. She has developed assays for analytes in the areas of endocrinology, fertility, cardiac markers and therapeutic drug monitoring. Dr. Evans has been involved with the American Association of Clinical Chemistry (AACC) since the 1980s, when she served as an officer in the Florida section and continued with local section activities in San Diego and Chicago. Her service to the AACC on the national level includes being elected to the board of directors, as national secretary, and as president in 2003. She chaired the Program Coordinating Commission twice, was one of the founding members of the Industry Division, and is vice chair of the 2008 Annual Meeting Organizing Committee. She currently chairs the Van Slyke Foundation Board of Trustees and the Awards Committee of the AACC.

Daryl Faulkner

Mr. Daryl Jay Faulkner is Independent Director of Venaxis, Inc. He was appointed to Board of Directors in the newly created position of Executive Chairman on January 19, 2009 and on February 10, 2009, was appointed to serve as interim Chief Executive Officer. Mr. Faulkner resigned from the position of interim Chief Executive Officer as of March 24, 2010. He continues to serve as a director. Mr. Faulkner has more than 25 years’ experience in developing and commercializing medical devices, drug and drug delivery systems, life science research tools, and molecular diagnostics. He served for approximately one year as President, CEO and a member of the Board of Directors of Digene Corporation, a Nasdaq-traded company prior to its acquisition in July 2007 by Qiagen (traded on Nasdaq’s Global Select market). He served as a consultant to Qiagen, and as co-chair of the executive integration steering committee with the CEO of Qiagen from July 2007 to January 2009. Currently, Mr. Faulkner also serves as a member of the board of directors of GenMark Diagnostics, Inc. (Nasdaq:GNMK), an emerging molecular diagnostics company traded on Nasdaq. Prior to joining Digene, Mr. Faulkner spent eight years with Invitrogen (now Life Technologies Corp. (Nasdaq:LIFE)) in a number of senior roles, including SVP Europe, SVP IVGN International Operations, and SVP of Strategic Business Units. Before Invitrogen, Mr. Faulkner’s career includes 15 years with the Fortune 100 Company, Abbott Laboratories, in which he held leadership positions in manufacturing operations and plant management. Mr. Faulkner received a degree in industrial relations from the University of North Carolina and a M.A. in business management from Webster University.

John Landon

Mr. John H. Landon is an Independent Director of Venaxis, Inc., since December 2008. Mr. Landon’s career includes more than 30 years of broad, multi-functional experience with the DuPont Company until his retirement in 1996. Prior to retiring from active management, Mr. Landon served as Vice President and General Manager of medical products for DuPont from 1992 to 1996. He had worldwide responsibility for all of DuPont’s medical product businesses, encompassing total annual sales of $1 billion and more than 5,000 employees. In addition to other director roles, Mr. Landon served as Chairman of the board of Cholestech Corporation prior to its 2007 sale to Inverness Medical and as a director of Digene Corporation prior to its 2007 sale to Qiagen. He currently is a member of the board of LipoScience, Inc., a publicly traded company (traded on the Nasdaq Global Select market) in the in vitro diagnostics industry developing and marketing diagnostic tests based on nuclear magnetic resonance technology. Mr. Landon is also a trustee of Christiana Care Health System and an advisor to Water Street Healthcare Partners. Mr. Landon received his B.S. in chemical engineering from the University of Arizona.

David Welch

Mr. David E. Welch is an Independent Director of Venaxis, Inc., since October 2004. Mr. Welch has served since April 2004 as Vice President and Chief Financial Officer of American Millennium Corporation, Inc., a private company (publicly traded until June 2010) located in Golden, Colorado. Mr. Welch formerly served as a director of PepperBall Technologies, Inc. He also is a self-employed financial consultant. From July 1999 to June 2002, Mr. Welch served as Chief Financial Officer, Secretary and Treasurer of Active Link Communications, Inc., another publicly traded company. During 1998, he served as Chief Information Officer for Language Management International, Inc., a multinational translation firm located in Denver, Colorado. From 1996 to 1997, he was Director of Information Systems for Micromedex, Inc., an electronic publishing firm, located in Denver, Colorado. Mr. Welch also serves on the board of directors of Communication Intelligence Corporation, a publicly traded company. He received a B.S. degree in accounting from the University of Colorado. Mr. Welch is a certified public accountant, licensed in the state of Colorado.

Stephen Williams

Dr. Stephen A. Williams, Ph.D., has been appointed as Independent Director of Venaxis, Inc., effective May 1, 2013. Dr. Williams is the Chief Medical Officer of SomaLogic, Inc., a position he has held since 2009. Prior thereto, he worked at Pfizer from 1989 until 2007. In 1989 he joined Pfizer U.K. in its experimental medicine division and worked on a variety of programs including asthma, irritable bowel syndrome, migraine, depression and urinary incontinence. Dr. Williams moved to the U.S. in 1993 with Pfizer and worked on programs in inflammatory bowel disease, stroke, psychosis and head injury. He created Pfizer’s Clinical Technology Group in 1997, which became a global group maintaining five research sites with the objective of validating clinical biomarkers and measurements, and was promoted to Pfizer Vice President in 2006. Dr. Williams’ undergraduate degree is a BSc (hons) in physiology. He trained as a physician at Charing Cross and Westminster Medical School, University of London, where he earned degrees in surgery and medicine (MB BS) and, following his internships, returned to the same institution for a Ph.D. in medicine and physiology. Subsequently, Dr. Williams performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne from 1989 to 1991. Dr. Williams was on the National Advisory Council to the National Institute of Biomedical Imaging and Bioengineering from 2003 to 2007 and on the Executive Committee of the FNIH-led Biomarkers Consortium from 2005 to 2007.

Joshua Drumm

Basic Compensation

Name Fiscal Year Total

Gail Schoettler

--

Stephen Lundy

639,224

Jeffrey McGonegal

400,452

Donald Hurd

394,910

Susan Evans

--

Daryl Faulkner

450,961

John Landon

--

David Welch

--

Stephen Williams

--

Joshua Drumm

--
As Of 30 Dec 2013
Search Stocks